Abstract:Background: The BRAF mutation V600E (BRAF(V600E)) is the most common genetic alteration in papillary thyroid carcinoma (PTC), while overexpression of X-linked inhibitor of apoptosis (XIAP) has been found in various tumors. Both of these events are implicated in carcinogenesis, tumor progression, recurrence, etc. There are few reports, however, of the BRAF V600E mutation and XIAP overexpression in PTC patients. The aim of this study was to investigate the frequency of the BRAF V600E mutation in PTC and its relationship to clinicopathological parameters and the expression of XIAP.Methods: Genomic DNA was extracted from 123 paraffin-embedded PTC tumor tissue samples and amplified for analysis of the V600E mutation in exon 15 of the BRAF gene by polymerase chain reaction. XIAP expression was examined by immunohistochemical methods in 46 PTCs, 18 benign nodular goiters, and 10 Hashimoto's thyroiditis samples.Results: The BRAF V600E mutation was found in 34.1% of PTC, and was especially prevalent in the classic type. BRAF V600E was significantly correlated with younger age at diagnosis (p=0.026), tumor size (p=0.009), and histological variants (p=0.024). There was a trend towards association with extrathyroidal invasion (p=0.067). By logistic regression analysis, a significant relationship was found between tumor size and the BRAF V600E mutation (p=0.03). XIAP was expressed in 82.6% of PTCs, which was a higher percentage than observed in the group of benign thyroid disorders (35.7%, p<0.001). Neither the intensity (p=0.611) nor the extent (p=0.723) of XIAP staining was correlated with the presence of BRAF V600E in PTC patients.Conclusions: These data indicate that BRAF V600E is associated some of the aggressive clinicopathological features of PTC including younger age at diagnosis, larger tumor size, and classic histological type, as well as also extrathyroidal invasion. XIAP-positive staining was more prevalent in PTCs than in the benign thyroid disorders. Although BRAF V600E and XIAP expression are commonly seen in PTC, their presence together seems unrelated.

Increased Expression of Valosin-Containing Protein (p97) Is Correlated With Disease Recurrence in Follicular Thyroid Cancer

High expression of valosin-containing protein predicts poor prognosis in patients with breast carcinoma

Association of Expression of Valosin Containing Protein with Prognosis of Gastric Carcinoma

Quantitative proteomics analysis of papillary thyroid carcinoma reveals PROS1, CLU, and LRG1 as potential novel prognostic protein biomarkers

Quantitative proteomics analysis of papillary thyroid carcinoma reveals Protein S, Clusterin, and Leucine-rich α-2-glycoprotein 1 as potential prognostic protein biomarkers

Relationship Between Preoperative Serum TSH Levels and Expression of VEGF in Papillary Thyroid Carcinoma

Conventional Ultrasound, Immunohistochemical Factors and BRAFV600E Mutation in Predicting Central Cervical Lymph Node Metastasis of Papillary Thyroid Carcinoma.

Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma

Pre-B-Cell Leukemia Transcription Factor 1 Regulates Expression of Valosin-Containing Protein, a Gene Involved in Cancer Growth

BRAFV600E expression in papillary thyroid carcinoma: potential diagnostic utility

Upregulation Of Protein Tyrosine Phosphatase Receptor Type C Associates To The Combination Of Hashimoto's Thyroiditis And Papillary Thyroid Carcinoma And Is Predictive Of A Poor Prognosis.

E74-like Factor 2 Regulates Valosin-Containing Protein Expression

Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.

Expression of cancer-associated fibroblast-related proteins in thyroid papillary carcinoma

BRAF V600E mutation and expression of its protein in papillary thyroid carcinoma

Targeting Valosin-Containing Protein Enhances the Efficacy of Radiation Therapy in Esophageal Squamous Cell Carcinoma.

Specific mutations in the D1–D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors

Braf(V600e) Mutation and X-Linked Inhibitor of Apoptosis Expression in Papillary Thyroid Carcinoma

Correlation of BRAF V600E Mutation and Clinical Characteristics in Coexistence of Papillary Thyroid Carcinoma and Hashimoto’s Thyroiditis

Expression of VEGF-C and VEGF-D Proteins in Papillary Thyroid Carcinoma and Their Relationship with Clinicopathologic Features

The clinicopathological features of follicular variant of papillary thyroid carcinoma